Esperion Therapeutics Inc (ESPR)
2.075
+0.01
(+0.48%)
USD |
NASDAQ |
May 03, 15:28
Esperion Therapeutics Total Long Term Debt (Quarterly): 261.60M for Dec. 31, 2023
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 261.60M |
September 30, 2023 | 261.16M |
June 30, 2023 | 260.74M |
March 31, 2023 | 260.32M |
December 31, 2022 | 259.90M |
September 30, 2022 | 259.49M |
June 30, 2022 | 259.08M |
March 31, 2022 | 258.68M |
December 31, 2021 | 258.28M |
September 30, 2021 | 272.51M |
Date | Value |
---|---|
June 30, 2021 | 272.10M |
March 31, 2021 | 271.69M |
December 31, 2020 | 179.37M |
September 30, 2020 | 0.00 |
June 30, 2020 | 0.00 |
March 31, 2020 | 0.00 |
December 31, 2019 | 0.00 |
September 30, 2019 | 0.00 |
June 30, 2019 | 0.00 |
March 31, 2019 | 0.00 |
Total Long Term Debt Definition
Total Long Term Debt is the current and non-current portion of debt that a company holds. Current Portion debt are obligations of a company lasting shorter than a year. This is found in a company's current liabilities on its balance sheet.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2019
272.51M
Maximum
Sep 2021
175.52M
Average
259.08M
Median
Jun 2022
Total Long Term Debt (Quarterly) Benchmarks
United Therapeutics Corp | 600.00M |
Dynavax Technologies Corp | 222.70M |
Heron Therapeutics Inc | 173.75M |
Aldeyra Therapeutics Inc | -- |
Deciphera Pharmaceuticals Inc | 0.00 |